Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

BRIUMVI U.S. net revenue of $119.7 million. Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

Story March 27 - Arbutus Biopharma: Arbutus is stripping back its workforce to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B.

derived from the roundleaf bat hepatitis B virus core antigen (RBHBcAg); the candidate molecule was named CR-T3-SEQ13. Multiple copies of epitopes on the surface of this particulate antigen promote ...